|
Cerebral Infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Apobec-1 could upregulate COX-2 expression in neurogenic cells by stabilizing COX-2 mRNA, and might aggravate injury of oxygen-glucose deprivation in neurogenic cells as well as in rats with cerebral ischemia.
|
23609497 |
2013 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Barrett Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Anaplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Apobec1 Promotes Neurotoxicity-Induced Dedifferentiation of Müller Glial Cells.
|
28150227 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
APOBEC1 emerged as the mere consistently hypomethylated gene in tumor samples with high number of in-frame indels.
|
29346513 |
2018 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Apobec-1 is an RNA-specific cytidine deaminase whose forced overexpression in transgenic animals is associated with hepatic carcinogenesis.
|
9797364 |
1998 |
|
Gastrointestinal Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Apobec-1 messenger RNA (mRNA) undergoes alternative splicing, generating a catalytically inactive peptide, apobec-T. We have examined apobec-1 gene expression in human gastrointestinal tumors and in colon cancer-derived cell lines.
|
9797364 |
1998 |
|
Malignant tumor of colon
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
Apobec-1 mRNA was detectable in normal and colon cancer tissue, metastatic nodules, and certain colon cancer-derived cell lines.
|
9797364 |
1998 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Apobec-1 mRNA was detectable in normal and colon cancer tissue, metastatic nodules, and certain colon cancer-derived cell lines.
|
9797364 |
1998 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
A Novel RNA Editing Sensor Tool and a Specific Agonist Determine Neuronal Protein Expression of RNA-Edited Glycine Receptors and Identify a Genomic APOBEC1 Dimorphism as a New Genetic Risk Factor of Epilepsy.
|
29375302 |
2017 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated apobec-1 introduction into HCA-7 (colorectal cancer) cells showed a dose-dependent increase in Cox-2 protein and stabilization of endogenous Cox-2 mRNA.
|
17875695 |
2007 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated apobec-1 introduction into HCA-7 (colorectal cancer) cells showed a dose-dependent increase in Cox-2 protein and stabilization of endogenous Cox-2 mRNA.
|
17875695 |
2007 |
|
Carcinogenesis
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
At an experimental level mouse APOBEC1 is remarkable among 12 mammalian A1 enzymes in that it represents a source of somatic mutations in mouse genome, potentially fueling oncogenesis.
|
31726973 |
2019 |
|
Neurofibromatosis 1
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme.
|
11727199 |
2002 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Corrigendum: A Novel RNA Editing Sensor Tool and a Specific Agonist Determine Neuronal Protein Expression of RNA-Edited Glycine Receptors and Identify a Genomic APOBEC1 Dimorphism as a New Genetic Risk Factor of Epilepsy.
|
31105523 |
2019 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Currently, there is no evidence that aberrant editing mediated by APOBEC-1 contributes to the tumorigenesis of natural human carcinomas.
|
10597235 |
1999 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Currently, there is no evidence that aberrant editing mediated by APOBEC-1 contributes to the tumorigenesis of natural human carcinomas.
|
10597235 |
1999 |
|
Intestinal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice.
|
17875695 |
2007 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
RGD |
Effects of a thyromimetic on apolipoprotein B-100 in rats.
|
11116209 |
2000 |
|
Hyperlipoproteinemias
|
0.200 |
Biomarker
|
disease |
RGD |
Effects of a thyromimetic on apolipoprotein B-100 in rats.
|
11116209 |
2000 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
First, these tumors express apobec-1 mRNA, the first demonstration, in humans, of its expression beyond the luminal gastrointestinal tract.
|
11727199 |
2002 |
|
Metabolic Syndrome X
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four genetic variants (APOA5_rs651821, EFCAB4B_rs4766165, ZNF259_rs2160669 and APOBEC1_rs10845640) were selected because they increased MetS risk after adjusting for covariates.
|
31544728 |
2019 |